Patterns of Pulmonary Complications Associated with SirolimusChhajed P.N.a · Dickenmann M.b · Bubendorf L.c · Mayr M.b · Steiger J.b · Tamm M.a
Divisions of aPulmonary Medicine and bTransplant Immunology and Nephrology, and cInstitute of Pathology, University Hospital Basel, Basel, Switzerland
Do you have an account?
- Rent for 48h to view
- Buy Cloud Access for unlimited viewing via different devices
- Synchronizing in the ReadCube Cloud
- Printing and saving restrictions apply
Rental: USD 8.50
Cloud: USD 20.00
Sirolimus inhibits human fibroblast cell proliferation in cell cultures from transbronchial biopsies of lung transplant recipients. However, a few cases of interstitial pneumonitis and bronchiolitis obliterans organizing pneumonia have been recently described in solid organ transplant recipients, including a fatality in a heart transplant recipient. We studied the patterns of pulmonary adverse effects associated with sirolimus in 4 renal transplant recipients who developed pulmonary opacities on chest radiograph, which were proved to be noninfectious in origin. Lung biopsy was performed to obtain histological diagnosis (3 interstitial pneumonitis, 1 necrotizing vasculitis). Symptoms were dyspnea (4), cough (2), hemoptysis (1), fever (1) and eyelid edema (1). Those with interstitial pneumonitis had bilateral basal opacities on chest X-ray, and histopathology showed mild lymphoplasmocytic interstitial inflammation, scattered intraalveolar epitheloid granulomas and a focal pattern of organizing pneumonia. Serum C-reactive protein (CRP) was elevated and bronchoalveolar lavage revealed lymphocytosis (77, 79.5 and 31%). The fourth patient had an opacity localized in the upper lobe, which progressed to both the lower lobes, and histopathology showed multifocal necroses of lung tissue with lymphoplasmocytic vasculitis and scattered granulomas. In this patient, the serum CRP level was not elevated and bronchoalveolar lavage was normal. Pulmonary symptoms and opacities on chest radiograph resolved and the serum CRP level became normal after sirolimus was stopped in all patients. Sirolimus may be a cause of interstitial pneumonitis or pulmonary vasculitis, and withdrawal of sirolimus is therapeutic.
© 2006 S. Karger AG, Basel
- Sehgal SN: Sirolimus: its discovery, biological properties, and mechanism of action. Transplant Proc 2003;35:S7–S14.
- Dupont P, Warrens AN: The evolving role of sirolimus in renal transplantation. QJM 2003;96:401–409.
- Marx SO, Jayaraman T, Go LO, Marks AR: Rapamycin-FKBP inhibits cell cycle regulators of proliferation in vascular smooth muscle cells. Circ Res 1995;76:412–417.
- Jenkins NP, Prendergast BD, Thomas M: Drug eluting coronary stents. BMJ 2002;325:1315–1316.
- Simler NR, Howell DC, Marshall RP, Goldsack NR, Hasleton PS, Laurent GJ, Chambers RC, Egan JJ: The rapamycin analogue SDZ RAD attenuates bleomycin-induced pulmonary fibrosis in rats. Eur Respir J 2002;19:1124–1127.
- Azzola A, Havryk A, Chhajed P, Hostettler K, Black J, Johnson P, Roth M, Glanville A, Tamm M: Everolimus and mycophenolate mofetil are potent inhibitors of fibroblast proliferation after lung transplantation. Transplantation 2004;77:275–280.
- Morelon E, Stern M, Israel-Biet D, Correas JM, Danel C, Mamzer-Bruneel MF, Peraldi MN, Kreis H: Characteristics of sirolimus-associated interstitial pneumonitis in renal transplant patients. Transplantation 2001;72:787–790.
- Mahalati K, Murphy MD, West ML: Bronchiolitis obliterans and organizing pneumonia in renal transplant recipients. Transplantation 2000;69:1531.
- Manito N, Kaplinsky EJ, Bernat R, Roca J, Castells E, Serrano T, Esplugas E: Fatal interstitial pneumonitis assiciated with sirolimus therapy in a heart transplant recipient. J Heart Lung Transplant 2004;23:780.
- Camus P, Fanton A, Bonniaud P, Camus C, Foucher P: Interstitial lung disease induced by drugs and radiation. Respiration 2004;71:301–326.
Groth CG, Backman L, Morales JM, Calne R, Kreis H, Lang P, Touraine JL, Claesson K, Campistol JM, Durand D, Wramner L, Brattstrom C, Charpentier B: Sirolimus (rapamycin)-based therapy in human renal transplantation: similar efficacy and different toxicity compared with cyclosporine. Sirolimus European Renal Transplant Study Group. Transplantation 1999;67:1036–1042.
- Kreis H, Cisterne JM, Land W, Wramner L, Squifflet JP, Abramowicz D, Campistol JM, Morales JM, Grinyo JM, Mourad G, Berthoux FC, Brattstrom C, Lebranchu Y, Vialtel P: Sirolimus in association with mycophenolate mofetil induction for the prevention of acute graft rejection in renal allograft recipients. Transplantation 2000;69:1252–1260.
- Radovancevic B, Vrtovec B: Sirolimus therapy in cardiac transplantation. Transplant Proc 2003;35:S171–S176.
- Mancini D, Pinney S, Burkhoff D, LaManca J, Itescu S, Burke E, Edwards N, Oz M, Marks AR: Use of rapamycin slows progression of cardiac transplantation vasculopathy. Circulation 2003;108:48–53.
- Fahrni JA, Berry GJ, Morris RE, Rosen GD: Rapamycin inhibits development of obliterative airway disease in a murine heterotopic airway transplant model. Transplantation 1997;63:533–537.
- Lennon A, Finan K, FitzGerald MX, McCormick PA: Interstitial pneumonitis associated with sirolimus (rapamycin) therapy after liver transplantation. Transplantation 2001;72:1166–1167.
- Saunders RN, Metcalfe MS, Nicholson ML: Rapamycin in transplantation: a review of the evidence. Kidney Int 2001;59:3–16.
- Kelly PA, Gruber SA, Behbod F, Kahan BD: Sirolimus, a new, potent immunosuppressive agent. Pharmacotherapy 1997;17:1148–1156.
- Mohaupt MG, Vogt B, Frey FJ: Sirolimus-associated eyelid edema in kidney transplant recipients. Transplantation 2001;72:162–164.
- Pham PT, Pham PC, Danovitch GM, Ross DJ, Gritsch HA, Kendrick EA, Singer J, Shah T, Wilkinson AH: Sirolimus-associated pulmonary toxicity. Transplantation 2004;77:1215–1220.
- Vlahakis NE, Rickman OB, Morgenthaler T: Sirolimus-associated diffuse alveolar hemorrhage. Mayo Clin Proc 2004;79:541–545.
- Pesenti S, Lauque D, Daste G, Boulay V, Pujazon MC, Carles P: Diffuse infiltrative lung disease associated with flecainide. Report of two cases. Respiration 2002;69:182–185.
- McWilliams TJ, Levvey BJ, Russell PA, Milne DG, Snell GI: Interstitial pneumonitis associated with sirolimus: a dilemma for lung transplantation. J Heart Lung Transplant 2003; 22:210–213.
- Singer SJ, Tiernan R, Sullivan EJ: Interstitial pneumonitis associated with sirolimus therapy in renal-transplant recipients. N Engl J Med 2000;343:1815–1816.
Article / Publication Details
Copyright / Drug Dosage / DisclaimerCopyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.